Inflammation in Alzheimer’s Disease and Molecular Genetics: Recent Update

Archivum Immunologiae et Therapiae Experimentalis

Volumn 63, Issue 5, 2015, Pages 333-344

  Zhang, Zhi Gang ^a   Li, Yan ^b   Ng, Cheung Toa ^a   Song, You Qiang ^a,c  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b QILU UNIVERSITY OF TECHNOLOGY   (China)

^c UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Alzheimer s disease; Genetics; GWAS; Inflammation; TREM2

Indexed keywords

CLUSTERIN; COMPLEMENT COMPONENT C3B RECEPTOR; HLA DRB1 ANTIGEN; HLA DRB5 ANTIGEN; MYOCYTE ENHANCER FACTOR 2; SYNAPTOJANIN; TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2; APOLIPOPROTEIN E; IMMUNOGLOBULIN RECEPTOR; MEMBRANE PROTEIN; TREM2 PROTEIN, HUMAN;

ALZHEIMER DISEASE; ASTROCYTE; CLU PROTEIN; COMPLEMENT SYSTEM; GENETIC ASSOCIATION; HUMAN; IMMUNE RESPONSE; MICROGLIA; MOLECULAR GENETICS; NERVE CELL; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; REVIEW; RISK ASSESSMENT; RISK FACTOR; ANIMAL; GENETICS; GENOME-WIDE ASSOCIATION STUDY; IMMUNOLOGY; INFLAMMATION; MOLECULAR BIOLOGY; PROCEDURES; RISK; TRENDS;

ALZHEIMER DISEASE; ANIMALS; APOLIPOPROTEINS E; GENOME-WIDE ASSOCIATION STUDY; HUMANS; INFLAMMATION; MEMBRANE GLYCOPROTEINS; MOLECULAR BIOLOGY; RECEPTORS, IMMUNOLOGIC; RISK;

EID: 84942198275     PISSN: 0004069X     EISSN: 16614917     Source Type: Journal    
DOI: 10.1007/s00005-015-0351-0     Document Type: Review

References (177)

1. Aiyaz M, Lupton MK, Proitsi P et al (2012) Complement activation as a biomarker for Alzheimer’s disease. Immunobiology 217:204–215
2. Aizenstein HJ, Nebes RD, Saxton JA et al (2008) Frequent amyloid deposition without significant cognitive impairment among the elderly. Arch Neurol 65:1509–1517
3. Akiyama H, Arai T, Kondo H et al (2000) Cell mediators of inflammation in the Alzheimer disease brain. Alzheimer Dis Assoc Disord 14(Suppl 1):S47–S53
4. Alzheimers Association (2012) 2012 Alzheimer’s disease facts and figures. Alzheimers Dement 8:131–168
5. Alzheimers Association (2013) 2013 Alzheimer’s disease facts and figures. Alzheimers Dement 9:208–245
6. Apelt J, Schliebs R (2001) Beta-amyloid-induced glial expression of both pro- and anti-inflammatory cytokines in cerebral cortex of aged transgenic Tg2576 mice with Alzheimer plaque pathology. Brain Res 894:21–30
7. Arijs I, De Hertogh G, Lemmens B et al (2012) Intestinal expression of SHIP in inflammatory bowel diseases. Gut 61:956–957
8. Avramopoulos D (2009) Genetics of Alzheimer’s disease: recent advances. Genome Med 1:34
9. Azizi G, Khannazer N, Mirshafiey A (2014) The potential role of chemokines in Alzheimer’s disease pathogenesis. Am J Alzheimers Dis Other Dement. doi:10.1177/1533317513518651
10. Bagyinszky E, Youn YC, An SS et al (2014) The genetics of Alzheimer’s disease. Clin Interv Aging 9:535–551
11. Baig S, Palmer LE, Owen MJ et al (2012) Clusterin mRNA and protein in Alzheimer’s disease. J Alzheimers Dis 28:337–344
12. Barnum SR (1995) Complement biosynthesis in the central nervous system. Crit Rev Oral Biol Med 6:132–146
13. Bauer J, Strauss S, Schreiter-Gasser U et al (1991) Interleukin-6 and alpha-2-macroglobulin indicate an acute-phase state in Alzheimer’s disease cortices. FEBS Lett 285:111–114
14. Bell RD, Winkler EA, Singh I et al (2012) Apolipoprotein E controls cerebrovascular integrity via cyclophilin A. Nature 485:512–516
15. Benarroch EE (2013) Microglia: multiple roles in surveillance, circuit shaping, and response to injury. Neurology 81:1079–1088
16. Benzing WC, Wujek JR, Ward EK et al (1999) Evidence for glial-mediated inflammation in aged APP(SW) transgenic mice. Neurobiol Aging 20:581–589
17. Bettens K, Sleegers K, Van Broeckhoven C (2013) Genetic insights in Alzheimer’s disease. Lancet Neurol 12:92–104
18. Blalock EM, Geddes JW, Chen KC et al (2004) Incipient Alzheimer’s disease: microarray correlation analyses reveal major transcriptional and tumor suppressor responses. Proc Natl Acad Sci USA 101:2173–2178
19. Blaschuk O, Burdzy K, Fritz IB (1983) Purification and characterization of a cell-aggregating factor (clusterin), the major glycoprotein in ram rete testis fluid. J Biol Chem 258:7714–7720
20. Blum-Degen D, Muller T, Kuhn W et al (1995) Interleukin-1 beta and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer’s and de novo Parkinson’s disease patients. Neurosci Lett 202:17–20
21. Bouchon A, Hernandez-Munain C, Cella M et al (2001) A DAP12-mediated pathway regulates expression of CC chemokine receptor 7 and maturation of human dendritic cells. J Exp Med 194:1111–1122
22. Boutajangout A, Wisniewski T (2013) The innate immune system in Alzheimer’s disease. Int J Cell Biol 2013:576383
23. Cagnin A, Brooks DJ, Kennedy AM et al (2001) In-vivo measurement of activated microglia in dementia. Lancet 358:461–467
24. Carver JA, Rekas A, Thorn DC et al (2003) Small heat-shock proteins and clusterin: intra- and extracellular molecular chaperones with a common mechanism of action and function? IUBMB Life 55:661–668
25. Choi-Miura NH, Takahashi Y, Nakano Y et al (1992) Identification of the disulfide bonds in human plasma protein SP-40, 40 (apolipoprotein-J). J Biochem 112:557–561
26. Clark RI, Tan SW, Péan CB et al (2013) MEF2 is an in vivo immune-metabolic switch. Cell 155:435–447
27. Colonna M (2003) TREMs in the immune system and beyond. Nat Rev Immunol 3:445–453
28. Conductier G, Blondeau N, Guyon A et al (2010) The role of monocyte chemoattractant protein MCP1/CCL2 in neuroinflammatory diseases. J Neuroimmunol 224:93–100
29. Cox D, Dale BM, Kashiwada M et al (2001) A regulatory role for Src homology 2 domain-containing inositol 5′-phosphatase (SHIP) in phagocytosis mediated by Fc gamma receptors and complement receptor 3 (alpha(M)beta(2); CD11b/CD18). J Exp Med 193:61–71
30. Craft JM, Watterson DM, Van Eldik LJ (2006) Human amyloid beta-induced neuroinflammation is an early event in neurodegeneration. Glia 53:484–490
31. Crehan H, Hardy J, Pocock J (2013) Blockage of CR1 prevents activation of rodent microglia. Neurobiol Dis 54:139–149
32. Cruchaga C, Haller G, Chakraverty S et al (2012) Rare variants in APP, PSEN1 and PSEN2 increase risk for AD in late-onset Alzheimer’s disease families. PLoS One 7:e31039
33. D’Ambrosio AL, Pinsky DJ, Connolly ES (2001) The role of the complement cascade in ischemia/reperfusion injury: implications for neuroprotection. Mol Med 7:367–382
34. Davis S, Laroche S (2003) What can rodent models tell us about cognitive decline in Alzheimer’s disease? Mol Neurobiol 27:249–276
35. de Cordoba SR, Rubinstein P (1986) Quantitative variations of the C3b/C4b receptor (CR1) in human erythrocytes are controlled by genes within the regulator of complement activation (RCA) gene cluster. J Exp Med 164:1274–1283
36. de Rivero Vaccari JP, Lotocki G et al (2008) A molecular platform in neurons regulates inflammation after spinal cord injury. J Neurosci 28:3404–3414
37. de Silva HV, Harmony JA, Stuart WD et al (1990) Apolipoprotein J: structure and tissue distribution. Biochemistry 29:5380–5389
38. DeMattos RB, O’dell MA, Parsadanian M et al (2002) Clusterin promotes amyloid plaque formation and is critical for neuritic toxicity in a mouse model of Alzheimer’s disease. Proc Natl Acad Sci USA 99:10843–10848
39. Downs-Kelly E, Schade AE, Hansel DE (2007) The role of HLA-G in gastrointestinal inflammatory disease and malignancy. Semin Cancer Biol 17:451–458
40. Du Yan S, Zhu H, Fu J et al (1997) Amyloid-beta peptide-receptor for advanced glycation endproduct interaction elicits neuronal expression of macrophage-colony stimulating factor: a proinflammatory pathway in Alzheimer disease. Proc Natl Acad Sci USA 94:5296–5301
41. Duan RS, Yang X, Chen ZG et al (2008) Decreased fractalkine and increased IP-10 expression in aged brain of APP(swe) transgenic mice. Neurochem Res 33:1085–1089
42. Fan R, DeFilippis K, Van Nostrand WE (2007) Induction of complement proteins in a mouse model for cerebral microvascular A beta deposition. J Neuroinflamm 4:22
43. Fann DY, Lee SY, Manzanero S et al (2013) Intravenous immunoglobulin suppresses NLRP1 and NLRP3 inflammasome-mediated neuronal death in ischemic stroke. Cell Death Dis 4:e790
44. Fillit H, Ding WH, Buee L et al (1991) Elevated circulating tumor necrosis factor levels in Alzheimer’s disease. Neurosci Lett 129:318–320
45. Fonseca MI, Kawas CH, Troncoso JC et al (2004) Neuronal localization of C1q in preclinical Alzheimer’s disease. Neurobiol Dis 15:40–46
46. Forneris F, Wu J, Gros P (2012) The modular serine proteases of the complement cascade. Curr Opin Struct Biol 22:333–341
47. Frank S, Burbach GJ, Bonin M et al (2008) TREM2 is upregulated in amyloid plaque-associated microglia in aged APP23 transgenic mice. Glia 56:1438–1447
48. Games D, Adams D, Alessandrini R et al (1995) Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta-amyloid precursor protein. Nature 373:523–527
49. Gasque P (2004) Complement: a unique innate immune sensor for danger signals. Mol Immunol 41:1089–1098
50. Gasque P, Fontaine M, Morgan BP (1995) Complement expression in human brain. Biosynthesis of terminal pathway components and regulators in human glial cells and cell lines. J Immunol 154:4726–4733
51. Geier SJ, Algate PA, Carlberg K et al (1997) The human SHIP gene is differentially expressed in cell lineages of the bone marrow and blood. Blood 89:1876–1885
52. Gemma C, Bickford PC (2007) Interleukin-1beta and caspase-1: players in the regulation of age-related cognitive dysfunction. Rev Neurosci 18:137–148
53. Giacobini E, Gold G (2013) Alzheimer disease therapy–moving from amyloid-beta to tau. Nat Rev Neurol 9:677–686
54. Giannakopoulos P, Kovari E, French LE et al (1998) Possible neuroprotective role of clusterin in Alzheimer’s disease: a quantitative immunocytochemical study. Acta Neuropathol 95:387–394
55. Giuriato S, Payrastre B, Drayer AL et al (1997) Tyrosine phosphorylation and relocation of SHIP are integrin-mediated in thrombin-stimulated human blood platelets. J Biol Chem 272:26857–26863
56. Griffin WS, Sheng JG, Royston MC et al (1998) Glial-neuronal interactions in Alzheimer’s disease: the potential role of a ‘cytokine cycle’ in disease progression. Brain Pathol 8:65–72
57. Guerreiro RJ, Gustafson DR, Hardy J (2012) The genetic architecture of Alzheimer’s disease: beyond APP, PSENs and APOE. Neurobiol Aging 33:437–456
58. Guerreiro R, Wojtas A, Bras J et al (2013) TREM2 variants in Alzheimer’s disease. N Engl J Med 368:117–127
59. Guo JT, Yu J, Grass D et al (2002) Inflammation-dependent cerebral deposition of serum amyloid a protein in a mouse model of amyloidosis. J Neurosci 22:5900–5909
60. Guo L, LaDu MJ, Van Eldik LJ (2004) A dual role for apolipoprotein e in neuroinflammation: anti- and pro-inflammatory activity. J Mol Neurosci 23:205–212
61. Halassa MM, Haydon PG (2010) Integrated brain circuits: astrocytic networks modulate neuronal activity and behavior. Annu Rev Physiol 72:335–355
62. Hamerman JA, Jarjoura JR, Humphrey MB et al (2006) Cutting edge: inhibition of TLR and FcR responses in macrophages by triggering receptor expressed on myeloid cells (TREM)-2 and DAP12. J Immunol 177:2051–2055
63. Harold D, Abraham R, Hollingworth P et al (2009) Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer’s disease. Nat Genet 41:1088–1093
64. Hazen AL, Smith MJ, Desponts C et al (2009) SHIP is required for a functional hematopoietic stem cell niche. Blood 113:2924–2933
65. Hazrati LN, Van Cauwenberghe C, Brooks PL et al (2012) Genetic association of CR1 with Alzheimer’s disease: a tentative disease mechanism. Neurobiol Aging 33:2949, e2945–2949, e2912
66. Hebert LE, Scherr PA, Bienias JL et al (2003) Alzheimer disease in the US population: prevalence estimates using the 2000 census. Arch Neurol 60:1119–1122
67. Heneka MT, Wiesinger H, Dumitrescu-Ozimek L et al (2001) Neuronal and glial coexpression of argininosuccinate synthetase and inducible nitric oxide synthase in Alzheimer disease. J Neuropathol Exp Neurol 60:906–916
68. Henneberger C, Papouin T, Oliet SH et al (2010) Long-term potentiation depends on release of d-serine from astrocytes. Nature 463:232–236
69. Hickman SE, El Khoury J (2014) TREM2 and the neuroimmunology of Alzheimer’s disease. Biochem Pharmacol 88:495–498
70. Hirsch EC, Hunot S (2009) Neuroinflammation in Parkinson’s disease: a target for neuroprotection? Lancet Neurol 8:382–397
71. Hochgrebe TT, Humphreys D, Wilson MR et al (1999) A reexamination of the role of clusterin as a complement regulator. Exp Cell Res 249:13–21
72. Hollingworth P, Harold D, Sims R et al (2011) Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer’s disease. Nat Genet 43:429–435
73. Holmes C, Boche D, Wilkinson D et al (2008) Long-term effects of Abeta42 immunisation in Alzheimer’s disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet 372:216–223
74. Hsieh CL, Koike M, Spusta SC et al (2009) A role for TREM2 ligands in the phagocytosis of apoptotic neuronal cells by microglia. J Neurochem 109:1144–1156
75. Huang Y, Mucke L (2012) Alzheimer mechanisms and therapeutic strategies. Cell 148:1204–1222
76. Huber M, Helgason CD, Damen JE et al (1999) The role of SHIP in growth factor induced signalling. Prog Biophys Mol Biol 71:423–434
77. Iida K, Mornaghi R, Nussenzweig V (1982) Complement receptor (CR1) deficiency in erythrocytes from patients with systemic lupus erythematosus. J Exp Med 155:1427–1438
78. Jankowsky JL, Patterson PH (1999) Cytokine and growth factor involvement in long-term potentiation. Mol Cell Neurosci 14:273–286
79. Jenne DE, Lowin B, Peitsch MC et al (1991) Clusterin (complement lysis inhibitor) forms a high density lipoprotein complex with apolipoprotein A-I in human plasma. J Biol Chem 266:11030–11036
80. Jiang H, Burdick D, Glabe CG et al (1994) beta-Amyloid activates complement by binding to a specific region of the collagen-like domain of the C1q A chain. J Immunol 152:5050–5059
81. Jiang H, Hampel H, Prvulovic D et al (2011) Elevated CSF levels of TACE activity and soluble TNF receptors in subjects with mild cognitive impairment and patients with Alzheimer’s disease. Mol Neurodegener 6:69
82. Jiang T, Yu JT, Zhu XC et al (2013) TREM2 in Alzheimer’s disease. Mol Neurobiol 48:180–185
83. Jonsson T, Stefansson H, Steinberg S et al (2013) Variant of TREM2 associated with the risk of Alzheimer’s disease. N Engl J Med 368:107–116
84. Kalesnikoff J, Lam V, Krystal G (2002) SHIP represses mast cell activation and reveals that IgE alone triggers signaling pathways which enhance normal mast cell survival. Mol Immunol 38:1201–1206
85. Katsel P, Tan W, Haroutunian V (2009) Gain in brain immunity in the oldest-old differentiates cognitively normal from demented individuals. PLoS One 4:e7642
86. Kerr WG (2011) Inhibitor and activator: dual functions for SHIP in immunity and cancer. Ann NY Acad Sci 1217:1–17
87. Khiem D, Cyster JG, Schwarz JJ et al (2008) A p38 MAPK-MEF2C pathway regulates B-cell proliferation. Proc Natl Acad Sci USA 105:17067–17072
88. Kim CH, Hangoc G, Cooper S et al (1999) Altered responsiveness to chemokines due to targeted disruption of SHIP. J Clin Invest 104:1751–1759
89. Kim JH, Kim JH, Jun HO et al (2010) Protective effect of clusterin from oxidative stress-induced apoptosis in human retinal pigment epithelial cells. Invest Ophthalmol Vis Sci 51:561–566
90. Klickstein LB, Bartow TJ, Miletic V et al (1988) Identification of distinct C3b and C4b recognition sites in the human C3b/C4b receptor (CR1, CD35) by deletion mutagenesis. J Exp Med 168:1699–1717
91. Klickstein LB, Barbashov SF, Liu T et al (1997) Complement receptor type 1 (CR1, CD35) is a receptor for C1q. Immunity 7:345–355
92. Korotzer AR, Watt J, Cribbs D et al (1995) Cultured rat microglia express C1q and receptor for C1q: implications for amyloid effects on microglia. Exp Neurol 134:214–221
93. Lambert JC, Heath S, Even G et al (2009) Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer’s disease. Nat Genet 41:1094–1099
94. Lambert JC, Ibrahim-Verbaas CA, Harold D et al (2013) Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer’s disease. Nat Genet 45:1452–1458
95. Lee SC, Zhao ML, Hirano A et al (1999) Inducible nitric oxide synthase immunoreactivity in the Alzheimer disease hippocampus: association with Hirano bodies, neurofibrillary tangles, and senile plaques. J Neuropathol Exp Neurol 58:1163–1169
96. Leifer D, Golden J, Kowall NW (1994) Myocyte-specific enhancer binding factor 2C expression in human brain development. Neuroscience 63:1067–1079
97. Liu L, Chan C (2014) The role of inflammasome in Alzheimer’s disease. Ageing Res Rev 15:6–15
98. Liu D, Niu ZX (2009) The structure, genetic polymorphisms, expression and biological functions of complement receptor type 1 (CR1/CD35). Immunopharmacol Immunotoxicol 31:524–535
99. Liu L, Martin R, Chan C (2013) Palmitate-activated astrocytes via serine palmitoyltransferase increase BACE1 in primary neurons by sphingomyelinases. Neurobiol Aging 34:540–550
100. Lyons GE, Micales BK, Schwarz J et al (1995) Expression of mef2 genes in the mouse central nervous system suggests a role in neuronal maturation. J Neurosci 15:5727–5738
101. Mandrekar-Colucci S, Landreth GE (2010) Microglia and inflammation in Alzheimer’s disease. CNS Neurol Disord Drug Targets 9:156–167
102. Maresco DL, Osborne JM, Cooney D et al (1999) The SH2-containing 5′-inositol phosphatase (SHIP) is tyrosine phosphorylated after Fc gamma receptor clustering in monocytes. J Immunol 162:6458–6465
103. Matsuoka Y, Picciano M, Malester B et al (2001) Inflammatory responses to amyloidosis in a transgenic mouse model of Alzheimer’s disease. Am J Pathol 158:1345–1354
104. May PC, Lampert-Etchells M, Johnson SA et al (1990) Dynamics of gene expression for a hippocampal glycoprotein elevated in Alzheimer’s disease and in response to experimental lesions in rat. Neuron 5:831–839
105. McGeer PL, McGeer EG (2002) The possible role of complement activation in Alzheimer disease. Trends Mol Med 8:519–523
106. McGeer PL, Itagaki S, Boyes BE et al (1988) Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson’s and Alzheimer’s disease brains. Neurology 38:1285–1291
107. Medway C, Morgan K (2014) Review: the genetics of Alzheimer’s disease; putting flesh on the bones. Neuropathol Appl Neurobiol 40:97–105
108. Meraz-Rios MA, Toral-Rios D, Franco-Bocanegra D et al (2013) Inflammatory process in Alzheimer’s disease. Front Integr Neurosci 7:59
109. Morgan BP, Gasque P (1996) Expression of complement in the brain: role in health and disease. Immunol Today 17:461–466
110. Mott RT, Ait-Ghezala G, Town T et al (2004) Neuronal expression of CD22: novel mechanism for inhibiting microglial proinflammatory cytokine production. Glia 46:369–379
111. Mrak RE, Griffin WS (2005) Potential inflammatory biomarkers in Alzheimer’s disease. J Alzheimers Dis 8:369–375
112. Mrak RE, Sheng JG, Griffin WS (1995) Glial cytokines in Alzheimer’s disease: review and pathogenic implications. Hum Pathol 26:816–823
113. Mulder SD, Nielsen HM, Blankenstein MA et al (2014) Apolipoproteins E and J interfere with amyloid-beta uptake by primary human astrocytes and microglia in vitro. Glia 62:493–503
114. Mullane K, Williams M (2013) Alzheimer’s therapeutics: continued clinical failures question the validity of the amyloid hypothesis-but what lies beyond? Biochem Pharmacol 85:289–305
115. Naj AC, Jun G, Beecham GW et al (2011) Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer’s disease. Nat Genet 43:436–441
116. Narayan P, Orte A, Clarke RW et al (2012) The extracellular chaperone clusterin sequesters oligomeric forms of the amyloid-beta(1-40) peptide. Nat Struct Mol Biol 19:79–83
117. Nataf S, Stahel PF, Davoust N et al (1999) Complement anaphylatoxin receptors on neurons: new tricks for old receptors? Trends Neurosci 22:397–402
118. Natarajan C, Bright JJ (2002) Peroxisome proliferator-activated receptor-gamma agonists inhibit experimental allergic encephalomyelitis by blocking IL-12 production, IL-12 signaling and Th1 differentiation. Genes Immun 3:59–70
119. Naya FJ, Olson E (1999) MEF2: a transcriptional target for signaling pathways controlling skeletal muscle growth and differentiation. Curr Opin Cell Biol 11:683–688
120. Neumann H, Takahashi K (2007) Essential role of the microglial triggering receptor expressed on myeloid cells-2 (TREM2) for central nervous tissue immune homeostasis. J Neuroimmunol 184:92–99
121. Orr CF, Rowe DB, Mizuno Y et al (2005) A possible role for humoral immunity in the pathogenesis of Parkinson’s disease. Brain 128(Pt 11):2665–2674
122. Otero K, Shinohara M, Zhao H et al (2012) TREM2 and beta-catenin regulate bone homeostasis by controlling the rate of osteoclastogenesis. J Immunol 188:2612–2621
123. Paloneva J, Manninen T, Christman G et al (2002) Mutations in two genes encoding different subunits of a receptor signaling complex result in an identical disease phenotype. Am J Hum Genet 71:656–662
124. Pavlov VA, Tracey KJ (2005) The cholinergic anti-inflammatory pathway. Brain Behav Immun 19:493–499
125. Pizza V, Agresta A, D’Acunto CW et al (2011) Neuroinflamm-aging and neurodegenerative diseases: an overview. CNS Neurol Disord Drug Targets 10:621–634
126. Potthoff MJ, Olson EN (2007) MEF2: a central regulator of diverse developmental programs. Development 134:4131–4140
127. Ransohoff RM (2007) The MHP36 line of murine neural stem cells expresses functional CXCR1 chemokine receptors that initiate chemotaxis in vitro. J Neuroimmunol 186:199 (author reply 200)
128. Ricklin D, Hajishengallis G, Yang K et al (2010) Complement: a key system for immune surveillance and homeostasis. Nat Immunol 11:785–797
129. Rogers J, Cooper NR, Webster S et al (1992) Complement activation by beta-amyloid in Alzheimer disease. Proc Natl Acad Sci USA 89:10016–10020
130. Ruan L, Kong Y, Wang JM et al (2010) Chemoattractants and receptors in Alzheimer’s disease. Front Biosci 2:504–514
131. Sahu A, Lambris JD (2001) Structure and biology of complement protein C3, a connecting link between innate and acquired immunity. Immunol Rev 180:35–48
132. Sastre M, Dewachter I, Landreth GE et al (2003) Nonsteroidal anti-inflammatory drugs and peroxisome proliferator-activated receptor-gamma agonists modulate immunostimulated processing of amyloid precursor protein through regulation of beta-secretase. J Neurosci 23:9796–9804
133. Savarin-Vuaillat C, Ransohoff RM (2007) Chemokines and chemokine receptors in neurological disease: raise, retain, or reduce? Neurotherapeutics 4:590–601
134. Scaltriti M, Bettuzzi S, Sharrard RM et al (2004) Clusterin overexpression in both malignant and nonmalignant prostate epithelial cells induces cell cycle arrest and apoptosis. Br J Cancer 91:1842–1850
135. Seshadri S, Fitzpatrick AL, Ikram MA et al (2010) Genome-wide analysis of genetic loci associated with Alzheimer disease. JAMA 303:1832–1840
136. Sessa G, Podini P, Mariani M et al (2004) Distribution and signaling of TREM2/DAP12, the receptor system mutated in human polycystic lipomembraneous osteodysplasia with sclerosing leukoencephalopathy dementia. Eur J Neurosci 20:2617–2628
137. Shen Y, Meri S (2003) Yin and Yang: complement activation and regulation in Alzheimer’s disease. Prog Neurobiol 70:463–472
138. Shen Y, Lue L, Yang L et al (2001) Complement activation by neurofibrillary tangles in Alzheimer’s disease. Neurosci Lett 305:165–168
139. Sherva R, Farrer LA (2011) Power and pitfalls of the genome-wide association study approach to identify genes for Alzheimer’s disease. Curr Psychiatry Rep 13:138–146
140. Sihlbom C, Davidsson P, Sjogren M et al (2008) Structural and quantitative comparison of cerebrospinal fluid glycoproteins in Alzheimer’s disease patients and healthy individuals. Neurochem Res 33:1332–1340
141. Singhrao SK, Neal JW, Rushmere NK et al (1999) Differential expression of individual complement regulators in the brain and choroid plexus. Lab Invest 79:1247–1259
142. Sly LM, Krzesicki RF, Brashler JR et al (2001) Endogenous brain cytokine mRNA and inflammatory responses to lipopolysaccharide are elevated in the Tg2576 transgenic mouse model of Alzheimer’s disease. Brain Res Bull 56:581–588
143. Sly LM, Rauh MJ, Kalesnikoff J et al (2003) SHIP, SHIP2, and PTEN activities are regulated in vivo by modulation of their protein levels: SHIP is up-regulated in macrophages and mast cells by lipopolysaccharide. Exp Hematol 31:1170–1181
144. Sly LM, Ho V, Antignano F et al (2007) The role of SHIP in macrophages. Front Biosci 12:2836–2848
145. Sofroniew MV, Vinters HV (2010) Astrocytes: biology and pathology. Acta Neuropathol 119:7–35
146. Strittmatter WJ, Saunders AM, Schmechel D et al (1993) Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci USA 90:1977–1981
147. Sudduth TL, Schmitt FA, Nelson PT et al (2013) Neuroinflammatory phenotype in early Alzheimer’s disease. Neurobiol Aging 34:1051–1059
148. Swanson BJ, Jack HM, Lyons GE (1998) Characterization of myocyte enhancer factor 2 (MEF2) expression in B and T cells: MEF2C is a B cell-restricted transcription factor in lymphocytes. Mol Immunol 35:445–458
149. Takahashi K, Rochford CD, Neumann H (2005) Clearance of apoptotic neurons without inflammation by microglial triggering receptor expressed on myeloid cells-2. J Exp Med 201:647–657
150. Tanzi RE (2012) The genetics of Alzheimer disease. Cold Spring Harbor Perspect Med 2 pii: a006296
151. Tarkowski E, Issa R, Sjogren M et al (2002) Increased intrathecal levels of the angiogenic factors VEGF and TGF-beta in Alzheimer’s disease and vascular dementia. Neurobiol Aging 23:237–243
152. Tenner AJ (1999) Membrane receptors for soluble defense collagens. Curr Opin Immunol 11:34–41
153. Thambisetty M, Simmons A, Velayudhan L et al (2010) Association of plasma clusterin concentration with severity, pathology, and progression in Alzheimer disease. Arch Gen Psychiatry 67:739–748
154. Thambisetty M, An Y, Nalls M et al (2013) Effect of complement CR1 on brain amyloid burden during aging and its modification by APOE genotype. Biol Psychiatry 73:422–428
155. Torres AR, Westover JB, Rosenspire AJ (2012) HLA immune function genes in autism. Autism Res Treat 2012:959073
156. Tosto G, Reitz C (2013) Genome-wide association studies in Alzheimer’s disease: a review. Curr Neurol Neurosci Rep 13:381
157. Town T, Nikolic V, Tan J (2005) The microglial “activation” continuum: from innate to adaptive responses. J Neuroinflammation 2:24
158. Trotta R, Parihar R, Yu J et al (2005) Differential expression of SHIP1 in CD56bright and CD56dim NK cells provides a molecular basis for distinct functional responses to monokine costimulation. Blood 105:3011–3018
159. Tuppo EE, Arias HR (2005) The role of inflammation in Alzheimer’s disease. Int J Biochem Cell Biol 37:289–305
160. Turnbull IR, Gilfillan S, Cella M et al (2006) Cutting edge: TREM-2 attenuates macrophage activation. J Immunol 177:3520–3524
161. Urbich C, Fritzenwanger M, Zeiher AM et al (2000) Laminar shear stress upregulates the complement-inhibitory protein clusterin: a novel potent defense mechanism against complement-induced endothelial cell activation. Circulation 101:352–355
162. Varnum MM, Ikezu T (2012) The classification of microglial activation phenotypes on neurodegeneration and regeneration in Alzheimer’s disease brain. Arch Immunol Ther Exp 60:251–266
163. Vodovotz Y, Lucia MS, Flanders KC et al (1996) Inducible nitric oxide synthase in tangle-bearing neurons of patients with Alzheimer’s disease. J Exp Med 184:1425–1433
164. Walker DG, Dalsing-Hernandez JE, Campbell NA et al (2009) Decreased expression of CD200 and CD200 receptor in Alzheimer’s disease: a potential mechanism leading to chronic inflammation. Exp Neurol 215:5–19
165. White JA, Manelli AM, Holmberg KH et al (2005) Differential effects of oligomeric and fibrillar amyloid-beta 1-42 on astrocyte-mediated inflammation. Neurobiol Dis 18:459–465
166. Wilker PR, Kohyama M, Sandau MM et al (2008) Transcription factor Mef2c is required for B cell proliferation and survival after antigen receptor stimulation. Nat Immunol 9:603–612
167. Wyatt A, Yerbury J, Poon S et al (2009) Chapter 6: the chaperone action of Clusterin and its putative role in quality control of extracellular protein folding. Adv Cancer Res 104:89–114
168. Wyss-Coray T (2006) Inflammation in Alzheimer disease: driving force, bystander or beneficial response? Nat Med 12:1005–1015
169. Wyss-Coray T, Mucke L (2002) Inflammation in neurodegenerative disease–a double-edged sword. Neuron 35:419–432
170. Wyss-Coray T, Rogers J (2012) Inflammation in Alzheimer disease-a brief review of the basic science and clinical literature. Cold Spring Harbor Perspect Med 2:a006346
171. Xie Z, Harris-White ME, Wals PA et al (2005) Apolipoprotein J (clusterin) activates rodent microglia in vivo and in vitro. J Neurochem 93:1038–1046
172. Yang LB, Li R, Meri S et al (2000) Deficiency of complement defense protein CD59 may contribute to neurodegeneration in Alzheimer’s disease. J Neurosci 20:7505–7509
173. Yerbury JJ, Poon S, Meehan S et al (2007) The extracellular chaperone clusterin influences amyloid formation and toxicity by interacting with prefibrillar structures. FASEB J 21:2312–2322
174. Yoshiyama Y, Lee VM, Trojanowski JQ (2013) Therapeutic strategies for tau mediated neurodegeneration. J Neurol Neurosurg Psychiatry 84:784–795
175. Yu JT, Tan L (2012) The role of clusterin in Alzheimer’s disease: pathways, pathogenesis, and therapy. Mol Neurobiol 45:314–326
176. Yu YT, Breitbart RE, Smoot LB et al (1992) Human myocyte-specific enhancer factor 2 comprises a group of tissue-restricted MADS box transcription factors. Genes Dev 6:1783–1798
177. Zou J, Crews FT (2012) Inflammasome-IL-1beta signaling mediates ethanol inhibition of hippocampal neurogenesis. Front Neurosci 6:77